Document is current
Any future updates will be listed below
-
Authors
Tashkin, Donald P.
Goodin, Thomas
Bowling, Alyssa
Price, Barry
Ozol-Godfrey, Ayca
Sharma, Sanjay
Sanjar, Shahin
-
Funding
Funding for this research was provided by:
Sunovion Pharmaceuticals Inc.
- License Information
-
More Information
Article History
Received: 6 February 2019
Accepted: 25 June 2019
First Online: 2 July 2019
Ethics approval and consent to participate
: The GEM1 and GEM2 study protocols were approved by the Quorom Review, Inc. Institutional Review Board for each study center and conducted according to the ethical principles of the Declaration of Helsinki and in compliance with the International Conference on Harmonization Good Clinical Practice guidelines. Written informed consent was obtained before enrollment into either study.
: The authors give their consent for publication.
: DPT has received non-financial support from Sunovion Inc. during the conduct of this study and personal fees from Sunovion Inc., AstraZeneca, Boehringer Ingelheim, and Innoviva, outside the submitted work. TG, AB, BP, AO-G, SSh, and SSa are employees of Sunovion Pharmaceuticals Inc.
